Prior rituximab correlates with less acute graft‐versus‐host disease and better survival in B‐cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation
作者： Voravit Ratanatharathorn , Brent Logan , Dan Wang , Mary Horowitz , Joseph P Uberti
DOI: 10.1111/J.1365-2141.2009.07674.X
关键词:
摘要: Summary Prior therapy with rituximab might attenuate disparate histocompatibility antigen presentation by B cells, thus decreased the risk of acute graft-versus-host disease (GVHD) and improved survival. We tested this hypothesis comparing outcomes 435 B-cell lymphoma patients who received allogeneic transplantation from 1999 to 2004 in Center for International Blood Marrow Transplant Research database: 179 subjects within 6 months prior (RTX cohort) 256 did not receive RTX (No-RTX cohort). The cohort had a significantly lower incidence treatment-related mortality (TRM) [relative (RR) = 0·68; 95% confidence interval (CI), 0·47–1·0; P = 0·05], grade II–IV (RR = 0·72; CI, 0·53–0·97; P = 0·03) III–IV GVHD (RR = 0·55; 0·34–0·91; P = 0·02). There was no difference chronic GVHD, progression or relapse. Progression-free survival (PFS) (RR = 0·68; CI 0·50–0·92; P = 0·01) overall (OS) (RR = 0·63; 0·46–0·86; P = 0·004) were better cohort. Prior correlated less similar TRM, PFS OS.
sci-hub.se 参考文章(36)
ME Reff, K Carner, KS Chambers, PC Chinn, JE Leonard, R Raab, RA Newman, N Hanna, DR Anderson, Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 Blood. ,vol. 83, pp. 435- 445 ,(1994) , 10.1182/BLOOD.V83.2.435.435
Barbarella Lucarelli, Maria L. Milani, Eva Arleo, Emilia Iannella, Francesca Mancini, Veronica Valle, Raffaella Cerretti, Maria S. De Propris, Anna P. Iori, Simonetta Pupella, Anna Guarini, Stefania Intoppa, Maria Gozzer, Robin Foà, Filippo Milano, Luigi Malandruccolo, Giovanni F. Torelli, B-cell concentration in the apheretic product predicts acute graft-versus-host disease and treatment-related mortality of allogeneic peripheral blood stem cell transplantation. Transplantation. ,vol. 85, pp. 386- 390 ,(2008) , 10.1097/TP.0B013E3181622E36
Joseph H. Antin, Donna Przepiorka, Rainer Storb, Claudio Anasetti, Richard A. Nash, Belinda R. Avalos, Finn B. Petersen, Voravit Ratanatharathorn, Joseph W. Fay, Donald Buell, Andrew M. Yeager, William Fitzsimmons, Chatchada Karanes, Pamela Bartels, Stella Davies, Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood. ,vol. 96, pp. 2062- 2068 ,(2000) , 10.1182/BLOOD.V96.6.2062
David R. Cox, Regression Models and Life-Tables Springer Series in Statistics. ,vol. 34, pp. 527- 541 ,(1992) , 10.1007/978-1-4612-4380-9_37
T. A. Davis, C. A. White, A. J. Grillo-López, W. S. Velásquez, B. Link, D. G. Maloney, R. O. Dillman, M. E. Williams, A. Mohrbacher, R. Weaver, S. Dowden, R. Levy, Single-Agent Monoclonal Antibody Efficacy in Bulky Non-Hodgkin's Lymphoma: Results of a Phase II Trial of Rituximab Journal of Clinical Oncology. ,vol. 17, pp. 1851- 1851 ,(1999) , 10.1200/JCO.1999.17.6.1851
E A Kurt-Jones, B Benacerraf, A K Abbas, K A HayGlass, M S Sy, D Liano, The role of antigen-presenting B cells in T cell priming in vivo. Studies of B cell-deficient mice. Journal of Immunology. ,vol. 140, pp. 3773- 3778 ,(1988)
P McLaughlin, A J Grillo-López, B K Link, R Levy, M S Czuczman, M E Williams, M R Heyman, I Bence-Bruckler, C A White, F Cabanillas, V Jain, A D Ho, J Lister, K Wey, D Shen, B K Dallaire, Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology. ,vol. 16, pp. 2825- 2833 ,(1998) , 10.1200/JCO.1998.16.8.2825
Ted A. Gooley, Wendy Leisenring, John Crowley, Barry E. Storer, Estimation of failure probabilities in the presence of competing risks: new representations of old estimators Statistics in Medicine. ,vol. 18, pp. 695- 706 ,(1999) , 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O
Roberto Stasi, Nichola Cooper, Giovanni Del Poeta, Elisa Stipa, Maria Laura Evangelista, Elisabetta Abruzzese, Sergio Amadori, Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell–depleting therapy with rituximab Blood. ,vol. 112, pp. 1147- 1150 ,(2008) , 10.1182/BLOOD-2007-12-129262
Taane G Clark, Douglas G Altman, Bianca L De Stavola, Quantification of the completeness of follow-up. The Lancet. ,vol. 359, pp. 1309- 1310 ,(2002) , 10.1016/S0140-6736(02)08272-7